NCT02664181View on ClinicalTrials.gov

Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

July 2, 2019

Study Completion Date

May 19, 2024

Conditions
Lung CancerNon-small Cell Lung Cancer
Interventions
DRUG

Nivolumab

Nivolumab will be given at 3mg/kg by IV every two weeks until progression

DRUG

oral decitabine

oral decitabine \~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.

DRUG

Tetrahydrouridine

Oral THU \~10 mg/kg twice weekly on consecutive days

Trial Locations (2)

20892

Center for Cancer Research, Bethesda

44118

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT02664181 - Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial | Biotech Hunter | Biotech Hunter